By Alexander Bueso
Date: Friday 20 Nov 2020
(Sharecast News) - The Food and Drug Administration has granted Emergency Use Approval for baricitinib, a treatment for Covid-19 developed jointly by Eli Lilly and Incyte, in combination with Gilead Sciences's remdesivir.
No recent information was found.
Currency | US Dollars |
Share Price | $ 67.76 |
Change Today | $ 0.49 |
% Change | 0.73 % |
52 Week High | $83.38 |
52 Week Low | $55.11 |
Volume | 719,661 |
Shares Issued | 193.43m |
Market Cap | $13,107m |
RiskGrade | 196 |
Strong Buy | 8 |
Buy | 2 |
Neutral | 12 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Time | Volume / Share Price |
15:38 | 100 @ $67.76 |
15:37 | 100 @ $67.78 |
15:37 | 100 @ $67.78 |
15:37 | 100 @ $67.78 |
15:37 | 100 @ $67.77 |
You are here: research